Table 3.
Confirmation of the top 18 T2DM-associated MVPs in LOLIPOP and FHS
| CpG identifier | Chr | Gene | Discovery, incident T2DM | LOLIPOP, incident T2DM | FHS, prevalent T2DM* | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | P | β | SE | P | |||
| cg19693031 | 1 | TXNIP | 0.52 | 0.46–0.6 | 0.68 | 0.62–0.75 | 1.2E-14 | −2.6E-02 | 2.7E-03 | 1.6E-21 |
| cg06500161 | 21 | ABCG1 | 1.65 | 1.45–1.89 | 1.44 | 1.31–1.58 | 2.6E-14 | 1.5E-02 | 1.8E-03 | 7.1E-17 |
| cg14476101 | 1 | PHGDH | 0.67 | 0.59–0.76 | 0.81 | 0.75–0.89 | 3.0E-06 | −1.6E-02 | 3.6E-03 | 1.5E-05 |
| cg14020176 | 17 | SLC9A3R1 | 1.63 | 1.4–1.9 | 1.14 | 1–1.29 | 4.3E-02 | 5.4E-03 | 1.5E-03 | 3.9E-04 |
| cg11024682 | 17 | SREBF1 | 1.56 | 1.35–1.79 | 1.40 | 1.26–1.57 | 2.2E-09 | 8.6E-03 | 1.6E-03 | 5.4E-08 |
| cg06397161 | 22 | SYNGR1 | 1.51 | 1.32–1.73 | 1.17 | 1.06–1.28 | 1.1E-03 | 9.6E-03 | 2.2E-03 | 1.6E-05 |
| cg00574958 | 11 | CPT1A | 0.69 | 0.61–0.78 | 0.80 | 0.74–0.88 | 1.1E-06 | −6.7E-03 | 7.9E-04 | 4.8E-17 |
| cg06235429 | 11 | NDUFV1 | 1.49 | 1.3–1.7 | 1.11 | 1–1.24 | 5.8E-02 | 2.4E-03 | 1.3E-03 | 6.5E-02 |
| cg05778424 | 17 | AKAP1 | 1.69 | 1.42–2.02 | 1.44 | 1.21–1.71 | 3.5E-05 | 4.9E-03 | 1.6E-03 | 2.5E-03 |
| cg11376147 | 11 | SLC43A1 | 0.68 | 0.59–0.77 | 0.85 | 0.74–0.97 | 1.5E-02 | −3.2E-03 | 1.2E-03 | 8.4E-03 |
| cg04816311 | 7 | C7orf50 | 1.51 | 1.31–1.75 | 1.13 | 1–1.27 | 4.4E-02 | 2.0E-02 | 3.2E-03 | 8.4E-10 |
| cg02711608 | 19 | SLC1A5 | 0.69 | 0.6–0.79 | 0.84 | 0.76–0.93 | 9.7E-04 | −7.9E-03 | 1.7E-03 | 2.0E-06 |
| cg08309687 | 21 | — | 0.68 | 0.6–0.78 | 0.82 | 0.74–0.91 | 1.9E-04 | −7.8E-03 | 3.0E-03 | 1.0E-02 |
| cg13514042 | 7 | — | 1.42 | 1.25–1.61 | 1.04 | 0.94–1.15 | 4.4E-01 | 1.8E-04 | 1.4E-03 | 9.0E-01 |
| cg08994060 | 10 | PFKFB3 | 0.65 | 0.55–0.76 | 0.81 | 0.72–0.92 | 6.6E-04 | −1.6E-02 | 2.5E-03 | 8.5E-10 |
| cg01676795 | 7 | POR | 1.56 | 1.33–1.84 | 1.09 | 0.95–1.26 | 2.2E-01 | 9.2E-03 | 2.4E-03 | 1.2E-04 |
| cg25130381 | 1 | SLC9A1 | 1.49 | 1.29–1.73 | 1.23 | 1.09–1.39 | 1.2E-03 | 6.5E-03 | 1.7E-03 | 1.7E-04 |
| cg11183227 | 15 | MAN2A2 | 1.49 | 1.29–1.72 | 1.08 | 0.97–1.2 | 1.9E-01 | 4.6E-03 | 2.0E-03 | 2.2E-02 |
MVPs and individual cells with confirmed association P < 0.05 appear in boldface type. FHS: 403 case and 2,204 control subjects). LOLIPOP: 1,074 case and 1,590 control subjects. OR: odds ratio for T2DM per 1 SD in methylation intensity. Chr, chromosome.
*
In FHS, β indicates difference in percentage DNAm intensity between case and control subjects, with adjustment for age, sex, principal components 1–3 (calculated from methylation data), batch, and family structure.